trial

Schizophrenia Sensory Gating Deficit With Quetiapine

NCTId NCT00536783
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 20 (estimated)
Sponsored by New Mexico VA Healthcare System
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
20 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2004-04
Primary completion
—
Eligibility
ALL · 18 Years · 18 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

New Mexico VA Healthcare SystemLead Sponsor
AstraZenecaCollaborator

Investigators

1
Jose M Canive, MDPrincipal Investigator

Sites

1 total
Albuquerque, United States

Facts & assertions

3 sourced
Enrollment
20
Phase
NA
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
New Mexico VA Healthcare System
company
collaborator
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jose M Canive, MD
person